Literature DB >> 3709624

Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes.

R E Vestal, K E Thummel, G D Mercer, J R Koup.   

Abstract

Theophylline, enriched with the stable isotopes 13C and 15N, was administered intravenously in a dose of 10 mg to 8 healthy men following single (200 mg) and multiple (200 mg 8-hourly for 5 days) oral dose administration of aminophylline. Total plasma clearance, volume of distribution, and half-time determined from the intravenous data were similar, demonstrating that the pharmacokinetics of theophylline after chronic dosing can be predicted from the pharmacokinetics of a single dose. With chronic oral dosing, however, the mean trough concentration was 12% higher at 9 a.m. than at 5 p.m., the end of the dose interval (3.94 +/- 0.55 vs. 3.50 +/- 0.45 micrograms X ml-1). The AUC following oral dosing was 25% higher in the multiple dose study than in the single dose study. Simulation analysis suggested that these results could be explained by diurnal variation in the clearance or absorption rate or a combination of both. Thus, the systemic availability of theophylline measured during a single dosage interval after chronic oral dosing to steady state would be overestimated in comparison with that measured after a single oral dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709624     DOI: 10.1007/bf00614207

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

1.  Dose-dependent kinetics of theophylline disposition in asthmatic children.

Authors:  M Weinberger; E Ginchansky
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

2.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

3.  A program for non-linear regression analysis to be used on desk-top computers.

Authors:  P Koeppe; C Hamann
Journal:  Comput Programs Biomed       Date:  1980-12

4.  Measurement of excretion characteristics of theophylline and its major metabolites.

Authors:  J H Jonkman; D Tang; R A Upton; S Riegelman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Intraindividual variability in theophylline pharmacokinetics: statistical verification in 39 of 60 healthy young adults.

Authors:  R A Upton; J F Thiercelin; T W Guentert; S M Wallace; J R Powell; L Sansom; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

6.  Cigarette smoking and theophylline metabolism: effects of cimetidine.

Authors:  B J Cusack; G W Dawson; G D Mercer; R E Vestal
Journal:  Clin Pharmacol Ther       Date:  1985-03       Impact factor: 6.875

7.  Nonlinear theophylline elimination.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

8.  Influence of chronic dosing on theophylline clearance.

Authors:  H Efthimiou; D J Morgan; L Ioannides-Demos; K Raymond; A J McLean
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

9.  Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms.

Authors:  D D Shen; M Fixley; D L Azarnoff
Journal:  J Pharm Sci       Date:  1978-07       Impact factor: 3.534

10.  Dose-dependent elimination kinetics of theophylline.

Authors:  L J Lesko
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

View more
  2 in total

1.  Lack of effect of ponsinomycin on the plasma pharmacokinetics of theophylline.

Authors:  W Couet; I Ingrand; B Reigner; J Girault; J Bizouard; J B Fourtillan
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.